4/A: P3 Health Director Ownership Corrected Post-Split, New RSU Grant

P3 Health Partners Director Thomas Price amends beneficial ownership post-reverse stock split and receives a new restricted stock unit grant.

Summary

• An amendment to Form 4 was filed to correct the beneficial ownership of Class A Common Stock for Director Thomas Edmunds Price.
• The correction addresses an error in Column 5 of Table I, which previously reported ownership prior to the company's 1-for-50 reverse stock split.
• The reverse stock split became effective on April 11, 2025.
• Director Price acquired 2,000 restricted stock units (RSUs) on August 6, 2025, under the P3 Health Partners Inc. 2021 Incentive Award Plan.
• Each RSU represents a right to receive one share of Class A common stock.
• The RSUs vest upon the earlier of the Company's 2026 annual stockholder meeting and the one-year anniversary of the grant date (August 6, 2026).
• Following the reported transactions and correction, Director Price beneficially owns 6,331 shares of Class A Common Stock.

Sentiment

Score: 6

Explanation: The filing primarily corrects an administrative error regarding beneficial ownership post-reverse stock split. The grant of restricted stock units to a director is a standard compensation practice, indicating continued alignment with company performance, which is a minor positive.

Positives

• Director Thomas Edmunds Price received a grant of 2,000 restricted stock units (RSUs), aligning his interests with long-term shareholder value.

Negatives

• The necessity to file an amended Form 4 indicates an initial administrative error in reporting beneficial ownership.

Future Outlook

The restricted stock units granted to Director Price are scheduled to vest upon the earlier of the Company's 2026 annual stockholder meeting and the one-year anniversary of the grant date (August 6, 2026).

Industry Context

NA

Related Party Transactions

• Grant of 2,000 restricted stock units to Director Thomas Edmunds Price.

Stakeholder Impact

• Shareholders: Clarification of director's beneficial ownership post-split and insight into director compensation structure.

Next Steps

• Vesting of 2,000 restricted stock units for Director Price, expected by August 6, 2026, or the 2026 annual stockholder meeting.

Key Dates

Recommendation

This filing is an administrative amendment correcting a director's beneficial ownership post-reverse stock split and reporting a routine restricted stock unit grant. It does not introduce new material information or significant changes to the company's financial or operational outlook that would necessitate a change in investment recommendation.

Keywords

P3 Health Partners, PIII, Form 4/A, SEC filing, beneficial ownership, restricted stock units, RSU, stock split, director compensation